JCI: The first phase of clinical trials of the nasal influenza vaccine was effective

February 4, 2021 // -- A recent study published in Journal of Clinical Investigation showed that the experimental single-dose nasal influenza vaccine is safe and produces a long-lasting immune response.
The research vaccine, called Ad4-H5-VTN, is a recombinant, replicated adenovirus vaccine designed to stimulate hemocoagulant antibodies, a protein attached to human cells on the surface of influenza viruses.
vaccine to be studied was developed by Emergent Biosolutions Inc. (Gaithersburg, Maryland).
nasal dosing, 28 participants received nasal dosing, 10 participants received oral capsules, and 25 participants received tonsil swabs.
(Photo Source: Www.pixabay.com) Participants who were vaccinated in the nose or through tonsil swabs showed significantly higher levels of H5-specific neutrality and antibodies than in the oral vaccine capsule group.
who received in-nasal vaccination distributed viral DNA for 2-4 weeks, but the median culture of the virus was only one day.
participants had evidence of H5-specific CD4 plus cd8 plus T cell response.
addition, volunteers receiving in-nasal vaccine had high serum and antibody levels 26 weeks after vaccination, and the level remained unchanged for 3 to 5 years after a single in-nasal vaccination.
the duration of the virus shedding was highly related to the median antibody response at week 26.
addition, in-nasal vaccines cause mucous membrane antibody reactions in the nose, mouth and rectum.
the study authors speculate that vector vaccines with replication capabilities may have an advantage over other types of vaccines because they can express viral proteins at higher levels and for longer periods of time.
, this type of vaccine induces a mucous membrane immune response, which is critical to limiting the spread of the virus that infects mucous membrane tissue.
the vaccine platform may be well suited to fight other viruses, including HIV and SARS-CoV-2, the authors said.
() Source: Intranasal influenza vaccine spurs strong immune response in Phase 1 Study Original source: Kenta Matsuda et al, A replication competent adenovirus-vectored influenza influenza vaccinees solution systemic and mucosal immunity, Journal of Clinical Investigation (2021). DOI: 10.1172/JCI140794